Skip to main content
Have a personal or library account? Click to login
Cetuximab in preoperative treatment of rectal cancer - term outcome of the XERT trial Cover

Cetuximab in preoperative treatment of rectal cancer - term outcome of the XERT trial

Radiology and Oncology
Volume 46 (2012): Issue 3 (September 2012)
By: ,  ,   and    
Open Access
|May 2012
References

References

  1. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer.2004;: 1731-40.
    Open DOISearch in Google Scholar
  2. Conde S, Borrego M, Teixeira T, Teixeira R, Corbal M, Sá A, et al. Impact of neoadjuvant chemoradiation on pathologic response and survival of patients with locally advanced rectal cancer.2010;: 51-9.
    Open DOISearch in Google Scholar
  3. Velenik V, Oblak I, Anderluh F. Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.2010;: 88.
    Open DOISearch in Google Scholar
  4. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.2000;: 701-8.
    Search in Google Scholar
  5. Nasu S, Ang KK, Fan Z, Milas L. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability.2001;: 474-7.
    Open DOISearch in Google Scholar
  6. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.2006;: 567-78.
    Open DOISearch in Google Scholar
  7. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.2010;: 21-8.
    Open DOISearch in Google Scholar
  8. Velenik V, Ocvirk J, Oblak I, Anderluh F. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.2011;: 244-50.
    Open DOISearch in Google Scholar
  9. Zhou Y, Boardman LA, Miller RC. Genetic testing for young-onset colorectal cancer: case report and evidence-based clinical guidelines.2010;: 57-61.
    Open DOISearch in Google Scholar
  10. Lewander A, Gao J, Adell G, Zhang H, Sun XF. Expression of NF-kappa B p65 phosphorylated at serine-536 in rectal cancer with or without preoperative radiotherapy.2011;: 279-84.
    Open DOISearch in Google Scholar
  11. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.2011;: 1535-46.
    Open DOISearch in Google Scholar
  12. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.2011;: 2011-9.
    Open DOISearch in Google Scholar
  13. Bengala C, Bettelli S, Bertolini F, Sartori G, Fontana A, Malavasi N, et al. Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.2010;: 1019-24.
    Open DOISearch in Google Scholar
  14. Davies JM, Trembath D, Deal AM, Funkhouser WK, Calvo BF, Finnegan T, et al. Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy.2011;: 114.
    Open DOISearch in Google Scholar
  15. Erben P, Strobel P, Horisberger K, Popa J, Bohn B, Hanfstein B, et al. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer. Int J2011;: 1032-8.
    Open DOISearch in Google Scholar
  16. Gaedcke J, Grade M, Jung K, Schirmer M, Jo P, Obermeyer C, et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.2010;: 76-81.
    Open DOISearch in Google Scholar
  17. Kim SY, Hong YS, Kim DY, Kim TW, Kim JH, Im SA, et al. Preoperative chemo-radiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.2011;: 677-83.
    Open DOISearch in Google Scholar
  18. Velenik V. Post-treatment surveillance in colorectal cancer.2010;: 135-41.
    Open DOISearch in Google Scholar
  19. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy.1997;: 19-23.
    Open DOISearch in Google Scholar
  20. Mihaylova I, Parvanova V, Velikova C, Kurteva G, Ivanova D. Degree of tumor regression after preoperative chemo-radiotherapy in locally advanced rectal cancer - Preliminary results.2011;: 237-42.
    Open DOISearch in Google Scholar
  21. Grimminger PP, Danenberg P, Dellas K, Arnold D, Rodel C, Machiels JP, et al. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.2011;: 3469-77.
    Open DOISearch in Google Scholar
  22. Hu-Lieskovan S, Vallbohmer D, Zhang W, Yang D, Pohl A, Labonte MJ, et al. EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.2011;: 5161-9.
    Open DOISearch in Google Scholar
  23. Fernández-Martos C, Pericay C, Salud A, Massuti B, Alonso V, Safont M, et al. Three-year outcomes of GCR-3: a phase II randomized trial comparing conventional preoperative chemoradiation (CRT) followed by surgery and postoperative adjuvant chemotherapy (CT) with induction CT followed by CRT and surgery in locally advanced rectal cancer. [Abstract].2011;: Abstract 3552.
    Open DOISearch in Google Scholar
  24. Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cáncer de Recto 3 study.2010;: 859-65.
    Open DOISearch in Google Scholar
  25. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.2009;: 663-71.
    Open DOISearch in Google Scholar
  26. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.2009;: 1408-17.
    Open DOISearch in Google Scholar
  27. Garcia-Aguilar J, Chen Z, Smith DD, Li W, Madoff RD, Cataldo P, et al. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.2011;: 486-93.
    Open DOISearch in Google Scholar
  28. Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES, Balducci M, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer.2005;: 752-60.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/v10019-012-0030-2 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 252 - 257
Published on: May 24, 2012
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
rectal cancer,
radio-chemotherapy,
cetuximab
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2012 Vaneja Velenik, Janja Ocvirk, Irena Oblak, Franc Anderluh, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.

Volume 46 (2012): Issue 3 (September 2012)
Previous article
Next article